Literature DB >> 7731694

Human ERG is a proto-oncogene with mitogenic and transforming activity.

A H Hart1, C M Corrick, M J Tymms, P J Hertzog, I Kola.   

Abstract

The ETS related gene, ERG, is one of 20 or more genes belonging to the ETS family of transcription factors. Translocation of the ERG gene t(21;22) results in the chimeric fusion transcript seen in approximately 10% of Ewings sarcomas. In addition, recent studies have shown that a reciprocal translocation t(21;16) of ERG gives rise to two aberrant transcripts seen in some forms of acute myeloid leukaemia. In vitro studies have linked the up regulation of ERG expression with stromal cell independence in erythroleukemic clones and shown that the ERG related genes ETS1 and ETS2 have a mitogenic and transforming activity when overexpressed in NIH3T3 cells. Interestingly ERGB/FLI-1, which is also involved in Ewings sarcoma translocations and shares a very high sequence identify with ERG has been reported to be unable to transform NIH3T3 cells. In this study we investigate the effects of overexpression of ERG on cell proliferation, factor dependence, growth in soft agar and tumorigenesis in nude mice. An ERG expression construct with the human ERG2 cDNA driven by the sheep metallothionein la promoter (sMTERG) was transfected into NIH3T3 cells. Clonal cell lines overexpressing ERG were established. The cell lines became morphologically altered, grew in low serum and serum free media and gave rise to colonies in soft agar suspension. Furthermore, we demonstrate that after subcutaneous injection these clones grow as solid tumors in nude mice. These data demonstrate that c-ERG is a proto-oncogene capable of transforming NIH3T3 cells. Therefore, overexpression or inappropriate expression of ERG may contribute to oncogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7731694

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.

Authors:  Wendell S Fortson; Shubhalaxmi Kayarthodi; Yasuo Fujimura; Huali Xu; Roland Matthews; William E Grizzle; Veena N Rao; Ganapathy K Bhat; E Shyam P Reddy
Journal:  Int J Oncol       Date:  2011-04-21       Impact factor: 5.650

2.  Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.

Authors:  Maisa Yoshimoto; Anthony M Joshua; Susan Chilton-Macneill; Jane Bayani; Shamini Selvarajah; Andrew J Evans; Maria Zielenska; Jeremy A Squire
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

3.  Retroviral transduction of TLS-ERG initiates a leukemogenic program in normal human hematopoietic cells.

Authors:  D S Pereira; C Dorrell; C Y Ito; O I Gan; B Murdoch; V N Rao; J P Zou; E S Reddy; J E Dick
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

4.  1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.

Authors:  Michele N Washington; Nancy L Weigel
Journal:  Endocrinology       Date:  2010-02-10       Impact factor: 4.736

5.  ETS-related gene is a novel prognostic factor in childhood acute lymphoblastic leukemia.

Authors:  Hai-Zhao Zhao; Ming Jia; Ze-Bin Luo; Xiao-Jun Xu; Si-Si Li; Jing-Ying Zhang; Xiao-Ping Guo; Yong-Min Tang
Journal:  Oncol Lett       Date:  2016-11-18       Impact factor: 2.967

Review 6.  Transcriptional control of the cell cycle in mammary gland development and tumorigenesis.

Authors:  Ricardo D Coletta; Paul Jedlicka; Arthur Gutierrez-Hartmann; Heide L Ford
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

Review 7.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

8.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

Review 9.  Is it important to decipher the heterogeneity of "normal karyotype AML"?

Authors:  Stephen D Nimer
Journal:  Best Pract Res Clin Haematol       Date:  2008-03       Impact factor: 3.020

10.  ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.

Authors:  Lukasz A Kacprzyk; Mark Laible; Tatjana Andrasiuk; Jan C Brase; Stefan T Börno; Maria Fälth; Ruprecht Kuner; Hans Lehrach; Michal R Schweiger; Holger Sültmann
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.